肝纤维化是肝硬化的病理组织学基础,主要表现为ECM分泌增加、降解减少,ECM在肝组织中沉积。肝星状细胞(HSC)是慢性肝病中ECM蛋白的主要来源。对HSC的干预无疑将成为防治肝纤维化的核心措施之一。近年研究发现生长抑素及其类似物可直接抑制活化HSC收缩[1],且可特异性抑制活化HSC Liver fibrosis is the histopathological basis of cirrhosis, mainly manifested as increased secretion of ECM, decreased degradation, and deposition of ECM in liver tissue. Hepatic stellate cells (HSCs) are the major source of ECM proteins in chronic liver disease. Intervention with HSC will undoubtedly become one of the core measures to prevent and treat liver fibrosis. Recent studies have found that somatostatin and its analogues can directly inhibit the activation of HSC contraction [1], and can specifically inhibit the activation of HSC